ADP-A2M4N7X19 / Adaptimmune, Noile-Immune Biotech - LARVOL DELTA

IL-7 and CCL19 Expression in Specific Peptide Enhanced Affinity Receptor T-cells Targeting MAGE-A4 Display Improved Survival and Ability to Induce Migration of Immune Cells (ASGCT 2022) - "Here we describe a next-generation SPEAR T-cell therapy (ADP-A2M4N7X19), targeting the MAGE-A4 tumor antigen peptide presented on HLA-A*02:01, that utilizes PRIME technology to secrete IL-7 and CCL19.3 These modifications are hypothesized to enhance proliferative and survival capabilities, as well as infiltration of other immune cells into MAGE-A4-positive tumors...SPEARHEAD-1: A Phase 2 trial of afamitresgene autoleucel (formerly ADP-A2M4) in patients with advanced synovial sarcoma or myxoid/round cell liposarcoma...Nat Biotechnol. 2018;36:346."

IO biomarker • Head and Neck Cancer • Liposarcoma • Lung Cancer • Non Small Cell Lung Cancer • Oncology • Ovarian Cancer • Solid Tumor • Squamous Cell Carcinoma • Squamous Cell Carcinoma of Head and Neck • Synovial Sarcoma • CCL19 • HLA-A • IL7 • MAGEA4

Preclinical Proof-of-Concept Data Supporting Future Clinical Development of Two New Cell Therapies Being Presented by Adaptimmune at ASGCT (GlobeNewswire) - "New next-gen SPEAR T-cells (ADP-A2M4N7X19) designed to enhance depth and durability of clinical response demonstrated enhanced proliferation, survival, and recruitment of immune cells in vitro....Engineered TILs (ADP-TILIL7) intended to improve clinical responses, produced levels of IL-7 shown to improve growth and survival in vitro....The Company is planning to initiate a Phase 1 trial with ADP-A2M4N7X19 in multiple solid tumors and a single-center, Phase 1 trial with ADP-TILIL7 for people with metastatic melanoma."

Preclinical • Melanoma • Oncology • Skin Cancer • Solid Tumor